Matthew Stanton, CFA
Stock Analyst at Jefferies
(1.17)
# 3,830
Out of 4,692 analysts
22
Total ratings
57.1%
Success rate
-3.7%
Average return
Main Sectors:
Stocks Rated by Matthew Stanton, CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Downgraded: Hold | $22 → $31 | $37.07 | -16.37% | 2 | Jul 23, 2026 | |
| CYRX Cryoport | Maintained: Hold | $9.5 → $13 | $16.00 | -18.75% | 6 | Jun 8, 2026 | |
| RGEN Repligen | Maintained: Hold | $135 → $142 | $180.98 | -21.54% | 7 | May 5, 2026 | |
| AZTA Azenta | Maintained: Buy | $42 → $35 | $32.65 | +7.20% | 5 | Apr 1, 2026 | |
| MRVI Maravai LifeSciences Holdings | Maintained: Buy | $10 | $7.64 | n/a | 1 | Mar 18, 2025 | |
| LAB Standard BioTools | Initiated Coverage: Buy | $3.25 | $0.6587 | n/a | 1 | Apr 4, 2024 |
BioLife Solutions
Jul 23, 2026
Downgraded: Hold
Price Target: $22 → $31
Current: $37.07
Upside: -16.37%
Cryoport
Jun 8, 2026
Maintained: Hold
Price Target: $9.5 → $13
Current: $16.00
Upside: -18.75%
Repligen
May 5, 2026
Maintained: Hold
Price Target: $135 → $142
Current: $180.98
Upside: -21.54%
Azenta
Apr 1, 2026
Maintained: Buy
Price Target: $42 → $35
Current: $32.65
Upside: +7.20%
Maravai LifeSciences Holdings
Mar 18, 2025
Maintained: Buy
Price Target: $10
Current: $7.64
Upside: n/a
Standard BioTools
Apr 4, 2024
Initiated Coverage: Buy
Price Target: $3.25
Current: $0.6587
Upside: n/a